1. Home
  2. NKTR vs GAB Comparison

NKTR vs GAB Comparison

Compare NKTR & GAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nektar Therapeutics

NKTR

Nektar Therapeutics

HOLD

Current Price

$72.79

Market Cap

2.2B

Sector

Health Care

ML Signal

HOLD

GAB

Gabelli Equity Trust Inc. (The)

HOLD

Current Price

$5.64

Market Cap

1.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
NKTR
GAB
Founded
1990
1986
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.2B
1.8B
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
NKTR
GAB
Price
$72.79
$5.64
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$146.67
N/A
AVG Volume (30 Days)
481.5K
590.6K
Earning Date
05-07-2026
01-01-0001
Dividend Yield
N/A
10.91%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$307,711,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
86.00
N/A
52 Week Low
$33.40
$5.28
52 Week High
$109.00
$6.37

Technical Indicators

Market Signals
Indicator
NKTR
GAB
Relative Strength Index (RSI) 49.04 46.03
Support Level $70.24 $5.60
Resistance Level $76.49 $5.72
Average True Range (ATR) 2.86 0.05
MACD -0.17 -0.01
Stochastic Oscillator 36.36 22.78

Price Performance

Historical Comparison
NKTR
GAB

About NKTR Nektar Therapeutics

Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255.

About GAB Gabelli Equity Trust Inc. (The)

Gabelli Equity Trust Inc is a non-diversified closed-end management investment company. Its primary investment objective is the long-term growth of capital with income as a secondary objective. The Fund invests at least its assets in equity securities under normal market conditions. Its equity portfolio includes common stock, preferred stock, convertible or exchangeable securities, and warrants and rights to purchase such securities selected by the Investment Adviser. The company invests in various sectors, of which Food & Beverage, Financial Services, Equipment and Supplies, Entertainment, Consumer Products, Health Care, Diversified Industrial, Business Services, Consumer Services and others.

Share on Social Networks: